Name: Respiratory Disease in the COVID-19 Era (en Inglés)
Price: 67.06 USD
Availability: InStock
Author: Okamoto, Masaki
ISBN: 9783036579160

portada Respiratory Disease in the COVID-19 Era (en Inglés)

Respiratory Disease in the COVID-19 Era (en Inglés)

Formato

Libro Físico

Editorial

Mdpi AG

Autor

Okamoto, Masaki

Idioma

Inglés

N° páginas

112

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 1.1 cm

Peso

0.44 kg.

ISBN13

9783036579160

Categorías

Farmacología

Respiratory Disease in the COVID-19 Era (en Inglés)

Okamoto, Masaki (Autor) · Mdpi AG · Tapa Dura

Libro Nuevo Importado

Envío: 16 a 23 días háb.

$ 134.12$ 67.06

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan más de 100 unidades

$ 67.06

Llega entre el 14 Jul y el 27 Jul a Quito, Pichincha. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Respiratory Disease in the COVID-19 Era (en Inglés)"

Coronavirus disease 2019 (COVID-19) is a new respiratory disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that caused a global pandemic. COVID-19 patients often develop acute respiratory distress syndrome (ARDS), which involves acute and lethal respiratory failure. In a meta-analysis, the median incidence of ARDS in COVID-19 patients was found to be 35 (2-79)%, while the mortality rate in COVID-19-associated ARDS patients was found to be 39 (12.5-73.1)% (Hasan, et al. Expert Rev Repoir Med. 2020; 14: 1149). As of 12 December 2021, 270,373,764 cases had been confirmed as COVID-19 and 5,321,321 cases had resulted in death, according to the World Health Organization webpage. Various symptoms such as persistent fatigue, myalgia, and insomnia can persist after recovery from COVID-19; these symptoms are called "long COVID-19". Patients with COVID-19 who survive but develop pulmonary fibrosis may experience persistent dyspnea upon exertion, a decrease in pulmonary function, and/or a radiological abnormal shadow. Antifibrotic drugs including nintedanib and pirfenidone are candidate drugs for the treatment of pulmonary fibrosis due to COVID-19; randomized controlled trials are ongoing.However, there are limited studies about respiratory disease caused by COVID-19. Given the clinical significance of this topic and its impact on clinical practice and public health, Medicina have published a Special Issue entitled "Respiratory Disease in the COVID-19 Era" with the aim of gathering accurate and up-to-date scientific information of this topic.